Ann: Validation for NNZ-2591 neurodevelopmental disorder pipeline, page-8

Well it’s good to see them making some progress here. But really they’re about 5 years slower than they should have been. Hopefully they’ll now push on and do a Ph 1 trial and get the ball rolling on this.

And I’m still annoyed that they’re locked out of pursuing 2591 for FXS, given that it’s not going anywhere in a hurry with trof. Though I will give them that these conditions probably reside with the same mob at the FDA as Rett so that should help a bit.

I’m not in anymore but hopefully for everyone else here the momentum will be sustained and the price will go somewhere reasonable.